morphine

MOR-feen

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists

High Alert

Severe pain (the 20 mg/mL oral solution concentration should only be used in opioid-tolerant patients).
Pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate (extended release).
Pulmonary edema.
Pain associated with MI.

Binds to opiate receptors in the CNS. Alters the perception of and response to painful stimuli while producing generalized CNS depression.

Therapeutic effects:

Decrease in severity of pain.

Absorption: Variably absorbed (about 30%) following oral administration. More reliably absorbed from rectal, SUBQ, and IM sites. Following epidural administration, systemic absorption and absorption into the intrathecal space via the meninges occurs.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Mostly metabolized by the liver. Active metabolites excreted renally.

Half-Life: Premature neonates: 10–20 hr; Neonates: 7.6 hr; Infants 1–3 mo: 6.2 hr; Children 6 mo–2.5 yr: 2.9 hr; Children 3–6 yr: 1–2 hr; Children 6–19 yr with sickle cell disease: 1.3 hr; Adults: 2–4 hr.

(analgesia)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	60 min	4–5 hr
PO-ER	unknown	3–4 hr	8–24 hr
IM	10–30 min	30–60 min	4–5 hr
SUBQ	20 min	50–90 min	4–5 hr
Rect	unknown	20–60 min	3–7 hr
IV	rapid	20 min	4–5 hr
Epidural	6–30 min	1 hr	up to 24 hr
IT	rapid (min)	unknown	up to 24 hr

Contraindicated in:

Hypersensitivity;
Some products contain tartrazine, bisulfites, or alcohol and should be avoided in patients with known hypersensitivity;
Acute, mild, intermittent, or postoperative pain (extended/sustained release);
Significant respiratory depression (extended release);
Acute or severe bronchial asthma (extended release);
Paralytic ileus (extended release).

Use Cautiously in:

Personal or family history of substance use disorder or mental illness;
Head trauma;
↑intracranial pressure;
Severe renal impairment;
Severe hepatic impairment;
Severe pulmonary disease;
Hypothyroidism;
Seizure disorder;
Adrenal insufficiency;
Undiagnosed abdominal pain;
Prostatic hyperplasia;
Patients undergoing procedures that rapidly ↓ pain (cordotomy, radiation); long-acting agents should be discontinued 24 hr before and replaced with short-acting agents;
OB:
Use during pregnancy only if potential maternal benefit justifies potential fetal risk. Chronic maternal treatment with opioids during pregnancy may result in neonatal opioid withdrawal syndrome
;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant ;
Pedi: Neonates and infants <3 mo (more susceptible to respiratory depression);
Pedi: Neonates (oral solution contains sodium benzoate, which can cause potentially fatal gasping syndrome);
Geri: ↑risk of respiratory depression in older adults; dose ↓ suggested.

CV: hypotension, bradycardia

Derm: flushing, itching, sweating

EENT: blurred vision, diplopia, miosis

Endo: adrenal insufficiency

GI: constipation, nausea, vomiting

GU: urinary retention

Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams

Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)

Misc: allodynia, opioid-induced hyperalgesia,

physical dependence

,

psychological dependence

, tolerance

Drug-drug:

Use with extreme caution in patients receiving MAO inhibitors within 14 days prior; may result in unpredictable, severe reactions; ↓ initial dose of morphine to 25% of usual dose.
Use with benzodiazepines or other CNS depressants, including other opioids, nonbenzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol, may cause profound sedation, respiratory depression, coma, and death; reserve concurrent use for when alternative treatment options are inadequate.
Drugs that affect serotonergic neurotransmitter systems, including tricyclic antidepressants, SSRIs, SNRIs, MAO inhibitors, TCAs, tramadol, trazodone, mirtazapine, 5-HT3 receptor antagonists, linezolid, methylene blue, and triptans, may ↑ risk of serotonin syndrome.
Mixed agonist/antagonist analgesics, including nalbuphine or butorphanol, and partial agonist analgesics, including buprenorphine, may ↓ morphine's analgesic effects and/or precipitate opioid withdrawal in physically dependent patients.
May ↑ the anticoagulant effect of warfarin.
Cimetidine may ↑ levels and risk of toxicity.
IV morphine may ↓ levels and antiplatelet effects of clopidogrel, prasugrel, and ticagrelor; consider IV antiplatelet agent as alternative in patients with acute coronary syndrome if morphine concurrently used.

Drug-Natural Products:

Kava-kava, valerian, or chamomile can ↑ risk of CNS depression.

Larger doses may be required during chronic therapy
PO Rect (Adults ≥50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients: 30 mg every 3–4 hr initially or once 24-hr opioid requirement is determined, convert to extended-release morphine by administering total daily oral morphine dose every 24 hr (as ER capsules), 50% of the total daily oral morphine dose every 12 hr (as MS Contin), or 33% of the total daily oral morphine dose every 8 hr (as MS Contin). See equianalgesic chart, Equianalgesic Dosing Guidelines. Dose of ER capsules should not exceed 1600 mg/day because of fumaric acid in formulation.
PO Rect (Adults and Children <50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients: 0.3 mg/kg every 3–4 hr initially.
PO (Children >1 mo): Prompt-release tablets and solution: 0.2–0.5 mg/kg every 4–6 hr as needed. Controlled-release tablet: 0.3–0.6 mg/kg every 12 hr.
IM IV SC (Adults ≥50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients: 4–10 mg every 3–4 hr. MI: 8–15 mg, for very severe pain additional smaller doses may be given every 3–4 hr.
IM IV SC (Adults and Children <50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients: 0.05–0.2 mg/kg every 3–4 hr; maximum: 15 mg/dose.
IM IV SC (Neonates ): 0.05 mg/kg every 4–8 hr, maximum dose: 0.1 mg/kg. Use preservative-free formulation.
IV SC (Adults ): Continuous infusion: 0.8–10 mg/hr; may be preceded by a bolus of 15 mg (infusion rates vary greatly; up to 80 mg/hr have been used).
IV SC (Children >1 mo): Continuous infusion, postoperative pain: 0.01–0.04 mg/kg/hr. Continuous infusion, sickle cell or cancer pain: 0.02–2.6 mg/kg/hr.
IV (Neonates ): Continuous infusion: 0.01–0.03 mg/kg/hr.
Epidural (Adults ): Intermittent injection: 5 mg/day (initially); if relief is not obtained at 60 min, 1–2 mg increments may be made (total dose not to exceed 10 mg/day). Continuous infusion: 2–4 mg/24 hr; may ↑ by 1–2 mg/day (up to 30 mg/day).
Epidural (Children >1 mo): 0.03–0.05 mg/kg, maximum dose: 0.1 mg/kg or 5 mg/24 hr. Use preservative-free formulation.
IT (Adults ): 0.2–1 mg. Use preservative-free formulation.

(Generic available)

Immediate-release tablets: 15 mg; 30 mg
Extended-release tablets (MS Contin): 15 mg; 30 mg; 60 mg; 100 mg; 200 mg
Extended-release capsules: 10 mg; 20 mg; 30 mg; 45 mg; 50 mg; 60 mg; 75 mg; 80 mg; 90 mg; 100 mg; 120 mg
Oral solution: 1 mg/mL; 10 mg/5 mL; 20 mg/5 mL; 5 mg/mL; 100 mg/5 mL
Rectal suppositories: 5 mg; 10 mg; 20 mg; 30 mg
Solution for epidural, IV injection (preservative-free): 0.5 mg/mL; 1 mg/mL
Solution for epidural or IT use (continuous microinfusion device; preservative-free): 10 mg/mL; 25 mg/mL
Solution for IM, SUBQ, IV injection: 1 mg/mL; 2 mg/mL; 4 mg/mL; 5 mg/mL; 8 mg/mL; 10 mg/mL; 25 mg/mL; 50 mg/mL
Solution for IV injection (PCA device): 1 mg/mL; 2 mg/mL; 3 mg/mL; 5 mg/mL

Assess type, location, and intensity of pain prior to and 1 hr following PO, SUBQ, and IM and 20 min (peak) following IV administration. When titrating opioid doses, ↑ of 25–50% should be administered until there is either a 50% ↓ in the patient’s pain rating on a numerical or visual analogue scale or the patient reports satisfactory pain relief. When titrating doses of short-acting morphine, a repeat dose can be safely administered at the time of the peak if previous dose is ineffective and side effects are minimal.
Assess BP, HR, and respiratory rate before and periodically during administration. If respiratory rate <10/min, assess level of sedation. Dose may need to be ↓ by 25–50%. Respiratory depression does not ↑ in severity, only in duration, with ↑ dose. Monitor for respiratory depression, especially during initiation or following dose ↑; serious, life-threatening, or fatal respiratory depression may occur. May cause sleep-related breathing disorders (central sleep apnea, sleep-related hypoxemia).
Patients on a continuous infusion should have additional bolus doses provided every 15–30 min as needed for breakthrough pain. The bolus dose is usually set to the amount of drug infused each hr by continuous infusion.
Patients taking extended-release morphine may require additional short-acting opioid doses for breakthrough pain. Doses of short-acting opioids should be equivalent to 10–20% of 24 hr total and given every 2 hr as needed.
An equianalgesic chart (see Equianalgesic Dosing Guidelines) should be used when changing routes or when changing from one opioid to another.
Geri: Assess older adults frequently, as they may be more sensitive to the effects of opioid analgesics and may experience side effects and respiratory complications more frequently.
Pedi: Assess pediatric patients frequently; children are more sensitive to the effects of opioid analgesics and may experience respiratory complications, excitability, and restlessness more frequently.
Prolonged use may lead to physical and psychological dependence and tolerance. This should not prevent patient from receiving adequate analgesia. Patients who receive morphine for pain rarely develop psychological dependence. Progressively higher doses may be required to relieve pain with long-term therapy; may ↑ risk of overdose. Prolonged use of opioids should be reserved for patients whose pain remains severe enough to require them and when alternative treatment options continue to be inadequate. Many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine.
Assess bowel function routinely. Institute prevention of constipation with ↑ intake of fluids and bulk and with laxatives to minimize constipating effects. Administer stimulant laxatives routinely if opioid use exceeds 2–3 days, unless contraindicated. Consider drugs for opioid-induced constipation.
Assess risk for opioid addiction, abuse, or misuse prior to administration. Abuse or misuse of extended-release preparations by crushing, chewing, snorting, or injecting dissolved product will result in uncontrolled delivery of morphine and can result in overdose and death.
Assess for opioid-induced hyperalgesia, which can appear as ↑ levels of pain on increasing the dose of the opioid, ↓ levels of pain on decreasing the dose of the opioid, or pain from ordinarily nonpainful stimuli (allodynia). This condition is different from tolerance. If a patient is suspected to be experiencing opioid-induced hyperalgesia, consider ↓ the dose of the current opioid or switching to a different opioid analgesic.

Lab Test Considerations:

May ↑ amylase and lipase.

Toxicity and Overdose:

If an opioid antagonist is required to reverse respiratory depression or coma, naloxone is the antidote. Dilute the 0.4-mg ampule of naloxone in 10 mL of 0.9% NaCl and administer 0.5 mL (0.02 mg) by IV push every 2 min. For children and adults weighing <40 kg, dilute 0.1 mg of naloxone in 10 mL of 0.9% NaCl for a concentration of 10 mcg/mL and administer 0.5 mcg/kg every 2 min. Titrate dose to avoid withdrawal, seizures, and severe pain.

High Alert: Do not confuse MS Contin with Oxycontin. Do not confuse morphine with hydromorphone. Do not confuse morphine (nonconcentrated oral liquid) with morphine (concentrated oral liquid).
Use only preservative-free formulations for neonates and for epidural and intrathecal routes in all patients.
Explain therapeutic value of medication prior to administration to enhance the analgesic effect.
- Regularly administered doses may be more effective than as needed administration. Analgesic is more effective if given before pain becomes severe.
- Coadministration with nonopioid analgesics may have additive analgesic effects and may permit lower doses.
- When transferring from other opioids or other forms of morphine to extended-release tablets, administer a total daily dose of oral morphine equivalent to previous daily dose (see Equianalgesic Dosing Guidelines) and divided every 8 hr (MS Contin), every 12 hr (MS Contin), or every 24 hr.
- Morphine should be discontinued gradually to prevent withdrawal symptoms after long-term use. For patients on long-acting agents who are physically opioid-dependent, initiate the taper by a small enough increment (no greater than 10–25% of total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2–4 wk. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper. Monitor frequently to manage pain and withdrawal symptoms (restlessness; lacrimation; rhinorrhea; yawning; perspiration; chills; myalgia; mydriasis; irritability; anxiety; backache; joint pain; weakness; abdominal cramps; insomnia; nausea; anorexia; vomiting; diarrhea; or ↑ BP, respiratory rate, or HR). If withdrawal symptoms occur, pause the taper for a period of time or ↑ the dose of opioid analgesic to the previous dose, and then proceed with a slower taper. Also, monitor patients for changes in mood, emergence of suicidal thoughts, or use of other substances. A multimodal approach to pain management may optimize the treatment of chronic pain and assist with the successful tapering of the opioid analgesic.
PO: Doses may be administered with food or milk to minimize GI irritation.
- Administer oral solution with properly calibrated measuring device; may be diluted in a glass of fruit juice just prior to administration to improve taste. Verify correct dose (mg) and correct volume (mL) prior to administration. Use an oral syringe when using 20 mg/mL concentration of oral solution.
- DNC: Swallow extended-release tablets whole; do not break, crush, dissolve, or chew (could result in rapid release and absorption of a potentially toxic dose).
- Extended-release capsules may be opened and the pellets sprinkled onto applesauce immediately prior to administration. Patients should rinse mouth and swallow to assure ingestion of entire dose. DNC: Pellets should not be chewed, crushed, or dissolved. Capsules may also be opened and sprinkled on approximately 10 mL of water and flushed while swirling through a prewetted 16 French gastrostomy tube fitted with a funnel at the port end. Additional water should be used to transfer and flush any remaining pellets. Do not administer extended-release capsules via a nasogastric tube.
MS Contin has been administered rectally.
IM: SC: IM is the preferred route for repeated doses. SUBQ administration may cause tissue irritation.
- Avoid IM administration in children. Fear of pain from IM injection may lead to inadequate pain control.
REMS: FDA strongly encourages health care providers to complete a REMS-compliant education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain, available at www.fda.gov/OpioidAnalgesicREMSBlueprint. Information on programs can be found at 1-800-503-0784 or www.opioidanalgesicrems.com.
Discuss availability of naloxone for emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing therapy, especially if patient has household members (including children) or other close contacts at risk for accidental exposure or overdose. Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concurrent use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. However, the presence of risk factors for overdose should not prevent the proper management of pain in any patient.
Administer undiluted. Do not use an in-line filter. Do not admix or administer other medications in epidural space for 48 hr after administration. Administer within 4 hr after removing from vial. Store in refrigerator; do not freeze.

IV Administration:

IV: Solution is colorless; do not administer discolored solution.
IV Push: Diluent: Do not dilute prior to injection.
Rate: High Alert: Administer slowly at 2.5–15 mg over 5 min. Rapid administration may lead to ↑ respiratory depression, hypotension, and circulatory collapse.
Continuous Infusion: Diluent: May be added to D5W, D10W, 0.9% NaCl, 0.45% NaCl, LR, dextrose/saline solution, or dextrose/LR. Concentration: 0.1–1 mg/mL or greater for continuous infusion.
Rate: Administer via infusion pump to control the rate. Dose should be titrated to ensure adequate pain relief without excessive sedation, respiratory depression, or hypotension. May be administered via patient-controlled analgesia pump.
Y-Site Compatibility:
- acetaminophen
- aldesleukin
- allopurinol
- amifostine
- amikacin
- aminocaproic acid
- aminophylline
- amiodarone
- anidulafungin
- argatroban
- arsenic trioxide
- ascorbic acid
- atropine
- aztreonam
- benztropine
- bivalirudin
- bleomycin
- bumetanide
- buprenorphine
- butorphanol
- caffeine citrate
- calcium chloride
- calcium gluconate
- cangrelor
- carboplatin
- carmustine
- caspofungin
- cefazolin
- cefotaxime
- cefotetan
- cefoxitin
- ceftaroline
- ceftazidime
- ceftolozane/tazobactam
- ceftriaxone
- cefuroxime
- chloramphenicol
- chlorpromazine
- cisatracurium
- cladribine
- clindamycin
- cyanocobalamin
- cyclophosphamide
- cyclosporine
- cytarabine
- dacarbazine
- dactinomycin
- daptomycin
- daunorubicin
- dexamethasone
- dexmedetomidine
- dexrazoxane
- digoxin
- diltiazem
- diphenhydramine
- dobutamine
- docetaxel
- dopamine
- doxorubicin hydrochloride
- doxycycline
- enalaprilat
- ephedrine
- epinephrine
- epirubicin
- epoetin alfa
- eptifibatide
- eravacycline
- ertapenem
- erythromycin
- esmolol
- etomidate
- etoposide
- etoposide phosphate
- famotidine
- fentanyl
- filgrastim
- fluconazole
- fludarabine
- fluorouracil
- foscarnet
- fosphenytoin
- gemcitabine
- gentamicin
- glycopyrrolate
- granisetron
- heparin
- hetastarch
- hydrocortisone
- hydromorphone
- idarubicin
- ifosfamide
- imipenem/cilastatin
- imipenem/cilastatin/relebactam
- irinotecan
- isavuconazonium
- isoproterenol
- ketorolac
- labetalol
- LR
- letermovir
- leucovorin
- lidocaine
- linezolid
- lorazepam
- magnesium sulfate
- mannitol
- melphalan
- meperidine
- meropenem
- meropenem/vaborbactam
- mesna
- methotrexate
- methylprednisolone
- metoclopramide
- metoprolol
- metronidazole
- midazolam
- milrinone
- mitoxantrone
- multivitamins
- mycophenolate
- nafcillin
- nalbuphine
- naloxone
- nicardipine
- nitroglycerin
- nitroprusside
- norepinephrine
- octreotide
- ondansetron
- oritavancin
- oxacillin
- oxaliplatin
- oxytocin
- paclitaxel
- palonosetron
- pamidronate
- papaverine
- pemetrexed
- penicillin G
- phenobarbital
- phentolamine
- phenylephrine
- phytonadione
- piperacillin/tazobactam
- plazomicin
- posaconazole
- potassium acetate
- potassium chloride
- procainamide
- prochlorperazine
- promethazine
- propranolol
- protamine
- pyridoxine
- remifentanil
- rituximab
- rocuronium
- sildenafil
- sodium acetate
- sodium bicarbonate
- succinylcholine
- sufentanil
- tacrolimus
- tedizolid
- theophylline
- thiamine
- thiotepa
- tigecycline
- tirofiban
- tobramycin
- topotecan
- vancomycin
- vasopressin
- vecuronium
- verapamil
- vinblastine
- vincristine
- vinorelbine
- voriconazole
- zidovudine
- zoledronic acid
Y-Site Incompatibility:
- alemtuzumab
- amphotericin B deoxycholate
- amphotericin B lipid complex
- amphotericin B liposomal
- azathioprine
- ceftobiprole
- dantrolene
- diazoxide
- doxorubicin liposomal
- folic acid
- ganciclovir
- gemtuzumab ozogamicin
- indomethacin
- micafungin
- mitomycin
- pentamidine
- pentobarbital
- phenytoin
- sargramostim
- trastuzumab

Explain purpose and side effects of morphine to patient. Instruct them to take medication as directed. Advise patient to read Patient Informationbefore starting and with each Rx refill in case of changes.
REMS: Instruct patient how and when to ask for pain medication. Do not stop taking without discussing with health care provider; may cause withdrawal symptoms if discontinued abruptly after prolonged use. Do not doses without discussing with health care provider; may lead to overdose. Discuss safe use, risks, and proper storage and disposal of opioid analgesics with patients and caregivers with each Rx. The Patient Counseling Guide is available at www.fda.gov/OpioidAnalgesicREMSPCG.
Medication may cause drowsiness or dizziness. Advise patient to call for assistance when ambulating and to avoid driving or other activities that require alertness until response to the medication is known.
Advise patient that morphine is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed. Store out of sight and reach of children, and in a location not accessible by others.
Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose. Inform patients and caregivers about various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (Rx, direct from pharmacist, or state programs). OTC naloxone nasal spray is available at pharmacies nationwide for overdose or accidental ingestion.
Advise patient to notify health care provider if pain control is not adequate or if severe or persistent side effects occur.
Advise patient to change positions slowly to minimize orthostatic hypotension.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care provider before taking any new medications.
Emphasize the importance of aggressive prevention of constipation with the use of morphine.
Caution patient to avoid concurrent use of alcohol or other CNS depressants with this medication.
Encourage patients who are immobilized or on prolonged bedrest to turn, cough, and breathe deeply every 2 hr to prevent atelectasis.
Advise patient that good oral hygiene, frequent mouth rinses, and sugarless gum or candy may decrease dry mouth.
Advise patient to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Inform patient of potential for neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Monitor neonate for signs and symptoms of withdrawal (irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, failure to gain weight); these usually occur the first days after birth. Monitor infants exposed to morphine through breast milk for excess sedation and respiratory depression. Chronic use may ↓ fertility in women and men.
Home Care Issues: High Alert: Explain to patient and family how and when to administer morphine and how to care for infusion equipment properly. Teach parents or caregivers how to accurately measure liquid medication and to use only the measuring device dispensed with the medication.

Decrease in severity of pain without a significant alteration in level of consciousness or respiratory status.
Decrease in symptoms of pulmonary edema.

~~AVINza,~~ Duramorph, ~~Embeda,~~ Infumorph, Mitigo, ~~Morphabond ER,~~ MS Contin, ~~Roxanol~~

Doloral, Kadian, M-Eslon, Morphine LP Epidural

Schedule II (C-II)

NDC Code

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0235- Morphine Sulfate
  - 0054-0235-24- 100 BLISTER PACK in 1 CARTON (0054-0235-24) / 1 TABLET in 1 BLISTER PACK

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0235- Morphine Sulfate
  - 0054-0235-25- 100 TABLET in 1 BOTTLE (0054-0235-25)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0236- Morphine Sulfate
  - 0054-0236-24- 100 BLISTER PACK in 1 CARTON (0054-0236-24) / 1 TABLET in 1 BLISTER PACK

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0236- Morphine Sulfate
  - 0054-0236-25- 100 TABLET in 1 BOTTLE (0054-0236-25)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0237- Morphine Sulfate
  - 0054-0237-49- 100 mL in 1 BOTTLE (0054-0237-49)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0237- Morphine Sulfate
  - 0054-0237-63- 500 mL in 1 BOTTLE (0054-0237-63)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0238- Morphine Sulfate
  - 0054-0238-49- 100 mL in 1 BOTTLE (0054-0238-49)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0238- Morphine Sulfate
  - 0054-0238-63- 500 mL in 1 BOTTLE (0054-0238-63)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0517- Morphine Sulfate
  - 0054-0517-41- 15 mL in 1 BOTTLE (0054-0517-41)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0517- Morphine Sulfate
  - 0054-0517-44- 30 mL in 1 BOTTLE (0054-0517-44)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0517- Morphine Sulfate
  - 0054-0517-50- 120 mL in 1 BOTTLE (0054-0517-50)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1277- Morphine Sulfate
  - 0115-1277-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1277-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1277- Morphine Sulfate
  - 0115-1277-03- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1277-03)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1277- Morphine Sulfate
  - 0115-1277-08- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1277-08)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1278- Morphine Sulfate
  - 0115-1278-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1278-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1278- Morphine Sulfate
  - 0115-1278-03- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1278-03)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1278- Morphine Sulfate
  - 0115-1278-08- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1278-08)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1279- Morphine Sulfate
  - 0115-1279-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1279-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1279- Morphine Sulfate
  - 0115-1279-03- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1279-03)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1279- Morphine Sulfate
  - 0115-1279-08- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1279-08)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1280- Morphine Sulfate
  - 0115-1280-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1280-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1280- Morphine Sulfate
  - 0115-1280-03- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1280-03)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1280- Morphine Sulfate
  - 0115-1280-08- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1280-08)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1281- Morphine Sulfate
  - 0115-1281-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1281-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1281- Morphine Sulfate
  - 0115-1281-03- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1281-03)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1281- Morphine Sulfate
  - 0115-1281-08- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1281-08)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1282- Morphine Sulfate
  - 0115-1282-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1282-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1282- Morphine Sulfate
  - 0115-1282-03- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1282-03)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1282- Morphine Sulfate
  - 0115-1282-08- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1282-08)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1479- Morphine Sulfate
  - 0115-1479-01- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1479-01)

0121- PAI Holdings, LLC dba PAI Pharma
- 0121-0825- Morphine Sulfate
  - 0121-0825-04- 118 mL in 1 BOTTLE (0121-0825-04)

0121- PAI Holdings, LLC dba PAI Pharma
- 0121-0825- Morphine Sulfate
  - 0121-0825-08- 240 mL in 1 BOTTLE (0121-0825-08)

0121- PAI Holdings, LLC dba PAI Pharma
- 0121-0825- Morphine Sulfate
  - 0121-0825-15- 1 BOTTLE in 1 CARTON (0121-0825-15) / 15 mL in 1 BOTTLE

0121- PAI Holdings, LLC dba PAI Pharma
- 0121-0904- Morphine Sulfate
  - 0121-0904-94- 3 TRAY in 1 CASE (0121-0904-94) / 10 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (0121-0904-05)

0228- Actavis Pharma, Inc.
- 0228-3090- Morphine sulfate
  - 0228-3090-11- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3090-11)

0228- Actavis Pharma, Inc.
- 0228-3091- Morphine sulfate
  - 0228-3091-11- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3091-11)

0228- Actavis Pharma, Inc.
- 0228-3092- Morphine sulfate
  - 0228-3092-11- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3092-11)

0228- Actavis Pharma, Inc.
- 0228-3093- Morphine sulfate
  - 0228-3093-11- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3093-11)

0228- Actavis Pharma, Inc.
- 0228-3116- Morphine sulfate
  - 0228-3116-11- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3116-11)

0228- Actavis Pharma, Inc.
- 0228-3117- Morphine sulfate
  - 0228-3117-11- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3117-11)

0228- Actavis Pharma, Inc.
- 0228-4270- Morphine sulfate
  - 0228-4270-11- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0228-4270-11)

0228- Actavis Pharma, Inc.
- 0228-4271- Morphine sulfate
  - 0228-4271-11- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0228-4271-11)

0228- Actavis Pharma, Inc.
- 0228-4311- Morphine sulfate
  - 0228-4311-11- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0228-4311-11)

0228- Actavis Pharma, Inc.
- 0228-4323- Morphine sulfate
  - 0228-4323-11- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0228-4323-11)

0228- Actavis Pharma, Inc.
- 0228-4347- Morphine sulfate
  - 0228-4347-11- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0228-4347-11)

0406- SpecGx LLC
- 0406-1516-
  - 0406-1516-06- 95 kg in 1 DRUM (0406-1516-06)

0406- SpecGx LLC
- 0406-1516-
  - 0406-1516-41- 10 kg in 1 PAIL (0406-1516-41)

0406- SpecGx LLC
- 0406-1516-
  - 0406-1516-42- 15 kg in 1 DRUM (0406-1516-42)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-05- .1 kg in 1 CONTAINER (0406-1521-05)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-06- 25 kg in 1 CONTAINER (0406-1521-06)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-25- 25 kg in 1 CONTAINER (0406-1521-25)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-40- .5 kg in 1 BOTTLE, GLASS (0406-1521-40)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-41- 10 kg in 1 PAIL (0406-1521-41)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-42- 95 kg in 1 DRUM (0406-1521-42)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-53- .005 kg in 1 BOTTLE (0406-1521-53)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-55- .025 kg in 1 BOTTLE (0406-1521-55)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-56- .05 kg in 1 BOTTLE (0406-1521-56)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-57- .1 kg in 1 BOTTLE (0406-1521-57)

0406- SpecGx LLC
- 0406-1521-
  0406-1521-99- 95 kg in 1 CONTAINER (0406-1521-99)

0406- SpecGx LLC
- 0406-5118- Morphine Sulfate
  0406-5118-01- 100 TABLET in 1 BOTTLE (0406-5118-01)

0406- SpecGx LLC
- 0406-5118- Morphine Sulfate
  - 0406-5118-62- 10 BLISTER PACK in 1 CARTON (0406-5118-62) / 10 TABLET in 1 BLISTER PACK

0406- SpecGx LLC
- 0406-5119- Morphine Sulfate
  - 0406-5119-01- 100 TABLET in 1 BOTTLE (0406-5119-01)

0406- SpecGx LLC
- 0406-5119- Morphine Sulfate
  - 0406-5119-62- 10 BLISTER PACK in 1 CARTON (0406-5119-62) / 10 TABLET in 1 BLISTER PACK

0406- SpecGx LLC
- 0406-8003- Morphine Sulfate
  - 0406-8003-12- 6 CARTON in 1 CASE (0406-8003-12) / 1 BOTTLE, PLASTIC in 1 CARTON / 120 mL in 1 BOTTLE, PLASTIC

0406- SpecGx LLC
- 0406-8003- Morphine Sulfate
  - 0406-8003-15- 6 CARTON in 1 CASE (0406-8003-15) / 1 BOTTLE, PLASTIC in 1 CARTON / 15 mL in 1 BOTTLE, PLASTIC

0406- SpecGx LLC
- 0406-8003- Morphine Sulfate
  - 0406-8003-24- 6 CARTON in 1 CASE (0406-8003-24) / 1 BOTTLE, PLASTIC in 1 CARTON / 240 mL in 1 BOTTLE, PLASTIC

0406- SpecGx LLC
- 0406-8003- Morphine Sulfate
  - 0406-8003-30- 6 CARTON in 1 CASE (0406-8003-30) / 1 BOTTLE, PLASTIC in 1 CARTON / 30 mL in 1 BOTTLE, PLASTIC

0406- SpecGx LLC
- 0406-8315- MORPHINE SULFATE
  - 0406-8315-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-8315-01)

0406- SpecGx LLC
- 0406-8315- MORPHINE SULFATE
  - 0406-8315-23- 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8315-23)

0406- SpecGx LLC
- 0406-8315- MORPHINE SULFATE
  - 0406-8315-62- 100 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8315-62)

0406- SpecGx LLC
- 0406-8320- MORPHINE SULFATE
  - 0406-8320-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-8320-01)

0406- SpecGx LLC
- 0406-8330- MORPHINE SULFATE
  - 0406-8330-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-8330-01)

0406- SpecGx LLC
- 0406-8330- MORPHINE SULFATE
  - 0406-8330-23- 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8330-23)

0406- SpecGx LLC
- 0406-8330- MORPHINE SULFATE
  - 0406-8330-62- 100 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8330-62)

0406- SpecGx LLC
- 0406-8380- MORPHINE SULFATE
  - 0406-8380-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-8380-01)

0406- SpecGx LLC
- 0406-8380- MORPHINE SULFATE
  - 0406-8380-23- 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8380-23)

0406- SpecGx LLC
- 0406-8380- MORPHINE SULFATE
  - 0406-8380-62- 100 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8380-62)

0406- SpecGx LLC
- 0406-8390- MORPHINE SULFATE
  - 0406-8390-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-8390-01)

0406- SpecGx LLC
- 0406-8390- MORPHINE SULFATE
  - 0406-8390-23- 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8390-23)

0406- SpecGx LLC
- 0406-8390- MORPHINE SULFATE
  - 0406-8390-62- 100 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0406-8390-62)

0409- Hospira, Inc.
- 0409-1134- Morphine Sulfate
  - 0409-1134-03- 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1134-03) / 20 mL in 1 VIAL, SINGLE-DOSE

0409- Hospira, Inc.
- 0409-1134- Morphine Sulfate
  - 0409-1134-05- 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1134-05) / 50 mL in 1 VIAL, SINGLE-DOSE

0409- Hospira, Inc.
- 0409-1890- Morphine Sulfate
  - 0409-1890-01- 10 CARTRIDGE in 1 CARTON (0409-1890-01) / 1 mL in 1 CARTRIDGE (0409-1890-03)

0409- Hospira, Inc.
- 0409-1890- Morphine Sulfate
  - 0409-1890-23- 10 SYRINGE in 1 CELLO PACK (0409-1890-23) / 1 mL in 1 SYRINGE (0409-1890-13)

0409- Hospira, Inc.
- 0409-1891- Morphine Sulfate
  - 0409-1891-01- 10 CARTRIDGE in 1 CARTON (0409-1891-01) / 1 mL in 1 CARTRIDGE (0409-1891-03)

0409- Hospira, Inc.
- 0409-1891- Morphine Sulfate
  - 0409-1891-23- 10 SYRINGE in 1 CELLO PACK (0409-1891-23) / 1 mL in 1 SYRINGE (0409-1891-13)

0409- Hospira, Inc.
- 0409-1892- Morphine Sulfate
  - 0409-1892-01- 10 CARTRIDGE in 1 CARTON (0409-1892-01) / 1 mL in 1 CARTRIDGE (0409-1892-03)

0409- Hospira, Inc.
- 0409-1893- Morphine Sulfate
  - 0409-1893-01- 10 CARTRIDGE in 1 CARTON (0409-1893-01) / 1 mL in 1 CARTRIDGE (0409-1893-03)

0409- Hospira, Inc.
- 0409-1893- Morphine Sulfate
  - 0409-1893-23- 10 SYRINGE in 1 CELLO PACK (0409-1893-23) / 1 mL in 1 SYRINGE (0409-1893-13)

0409- Hospira, Inc.
- 0409-1896- Morphine Sulfate
  - 0409-1896-20- 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1896-20) / 20 mL in 1 VIAL, SINGLE-DOSE

0409- Hospira, Inc.
- 0409-2022- Morphine sulfate
  - 0409-2022-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-2022-01) / 50 mL in 1 VIAL, SINGLE-DOSE

0409- Hospira, Inc.
- 0409-3814- Morphine Sulfate
  - 0409-3814-12- 5 VIAL, GLASS in 1 CARTON (0409-3814-12) / 10 mL in 1 VIAL, GLASS (0409-3814-11)

0409- Hospira, Inc.
- 0409-3815- Morphine Sulfate
  - 0409-3815-12- 5 VIAL, GLASS in 1 CARTON (0409-3815-12) / 10 mL in 1 VIAL, GLASS (0409-3815-11)

0574- Padagis US LLC
- 0574-7110- Morphine Sulfate
  - 0574-7110-12- 12 PACKET in 1 BOX (0574-7110-12) / 1 SUPPOSITORY in 1 PACKET

0574- Padagis US LLC
- 0574-7112- Morphine Sulfate
  - 0574-7112-12- 12 PACKET in 1 BOX (0574-7112-12) / 1 SUPPOSITORY in 1 PACKET

0574- Padagis US LLC
- 0574-7114- Morphine Sulfate
  - 0574-7114-12- 12 PACKET in 1 BOX (0574-7114-12) / 1 SUPPOSITORY in 1 PACKET

0574- Padagis US LLC
- 0574-7116- Morphine Sulfate
  - 0574-7116-12- 12 PACKET in 1 BOX (0574-7116-12) / 1 SUPPOSITORY in 1 PACKET

0641- Hikma Pharmaceuticals USA Inc.
- 0641-6019- Duramorph
  - 0641-6019-10- 10 AMPULE in 1 CARTON (0641-6019-10) / 10 mL in 1 AMPULE (0641-6019-01)

0641- Hikma Pharmaceuticals USA Inc.
- 0641-6020- Duramorph
  - 0641-6020-10- 10 AMPULE in 1 CARTON (0641-6020-10) / 10 mL in 1 AMPULE (0641-6020-01)

0641- Hikma Pharmaceuticals USA Inc.
- 0641-6039- INFUMORPH 200
  - 0641-6039-01- 20 mL in 1 AMPULE (0641-6039-01)

0641- Hikma Pharmaceuticals USA Inc.
- 0641-6040- INFUMORPH 500
  - 0641-6040-01- 20 mL in 1 AMPULE (0641-6040-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Contr. Subst. Schedule ⬆ ⬇

Code ⬆